Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
Golfers swing into action for the Chilterns Neuro Centre
Wednesday 11 June, 2025 The Chilterns Neuro Centre is delighted by the…
